Qualigen Therapeutics Inc

-0.02 (-2.98%)
Equity Investments, Earnings Announcements

Qualigen Therapeutics To Acquire Majority Stake In Diagnostics Technology Company Nanosynex

Published: 05/03/2022 13:37 GMT
Qualigen Therapeutics Inc (QLGN) - Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company Nanosynex.
Qualigen - Deal for Controlling Interest in Nanosynex to Be Primarily Comprised of Stock-for-stock Acquisition With Nanosynex Controlling Shareholder.
Qualigen Therapeutics Inc - Purchase of Controlling Interest in Nanosynex Will Be Comprised of an Initial $600,000 Cash Investment.
Qualigen - Expects to Consolidate Financial Results of Nanosynex, & Provide Future Milestone-based Funding Leading to Commercialization of Technology.
Revenue is expected to be $1.31 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $1.46 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.